ATE447959T1 - Methode zur reduktion des schmerzempfindens - Google Patents

Methode zur reduktion des schmerzempfindens

Info

Publication number
ATE447959T1
ATE447959T1 AT01982091T AT01982091T ATE447959T1 AT E447959 T1 ATE447959 T1 AT E447959T1 AT 01982091 T AT01982091 T AT 01982091T AT 01982091 T AT01982091 T AT 01982091T AT E447959 T1 ATE447959 T1 AT E447959T1
Authority
AT
Austria
Prior art keywords
pain
sensation
reducing
anolgs
saxitoxin
Prior art date
Application number
AT01982091T
Other languages
English (en)
Inventor
Qingbin Dong
Frank Haykong Shum
Original Assignee
Wex Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wex Medical Ltd filed Critical Wex Medical Ltd
Application granted granted Critical
Publication of ATE447959T1 publication Critical patent/ATE447959T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Laser Surgery Devices (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT01982091T 2000-09-18 2001-09-11 Methode zur reduktion des schmerzempfindens ATE447959T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB001245171A CN1284536C (zh) 2000-09-18 2000-09-18 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
PCT/CN2001/001391 WO2002022129A1 (en) 2000-09-18 2001-09-11 A method of analgesia

Publications (1)

Publication Number Publication Date
ATE447959T1 true ATE447959T1 (de) 2009-11-15

Family

ID=4590472

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04022073T ATE542534T1 (de) 2000-09-18 2001-09-11 Methode zur schmerzbekämpfung
AT01982091T ATE447959T1 (de) 2000-09-18 2001-09-11 Methode zur reduktion des schmerzempfindens

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04022073T ATE542534T1 (de) 2000-09-18 2001-09-11 Methode zur schmerzbekämpfung

Country Status (26)

Country Link
US (1) US6407088B1 (de)
EP (3) EP1320369B1 (de)
JP (1) JP2004508404A (de)
KR (2) KR20070112864A (de)
CN (1) CN1284536C (de)
AT (2) ATE542534T1 (de)
AU (1) AU2002213785A1 (de)
BG (1) BG107690A (de)
BR (1) BR0113961A (de)
CA (1) CA2421562C (de)
DE (1) DE60140466D1 (de)
EA (1) EA004870B1 (de)
EE (1) EE200300106A (de)
ES (1) ES2435463T3 (de)
HR (1) HRP20030202A2 (de)
HU (1) HUP0302677A3 (de)
IL (1) IL154342A0 (de)
IS (1) IS6719A (de)
MX (1) MXPA03002389A (de)
NO (1) NO323960B1 (de)
PL (1) PL360616A1 (de)
SK (1) SK3732003A3 (de)
UA (1) UA76960C2 (de)
WO (1) WO2002022129A1 (de)
YU (1) YU17103A (de)
ZA (1) ZA200301852B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047869A1 (en) 1997-04-22 1998-10-29 Cocensys, Inc. Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof
CN1236773C (zh) 2000-11-22 2006-01-18 南宁枫叶药业有限公司 用于镇痛、麻醉或治疗药物依赖性的制剂
US7119062B1 (en) 2001-02-23 2006-10-10 Neucoll, Inc. Methods and compositions for improved articular surgery using collagen
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
CN1203860C (zh) * 2001-06-22 2005-06-01 威克斯医药有限公司 钠离子通道阻断剂和阿司匹林在制备用于对哺乳动物进行协同镇痛的药物中的应用
CN1585642A (zh) 2001-11-15 2005-02-23 微观藻类公司 包含3,4－丙炔基全氢化嘌呤的药物组合物及其在阻滞神经元传递方面的应用
WO2004013637A1 (en) * 2002-08-01 2004-02-12 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 37 (gpr37)
EP1589959A2 (de) * 2003-01-30 2005-11-02 Dynogen Pharmaceuticals Inc. Verfahren zur behandlung von erkrankungen der unteren harnwege mit natriumkanalmodulatoren
CN1568999A (zh) 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
JP2005154368A (ja) * 2003-11-27 2005-06-16 Teikoku Seiyaku Co Ltd ジソピラミド含有神経因性疼痛の鎮痛剤
AU2005244105B2 (en) * 2004-05-07 2011-10-06 Algenis Spa Phycotoxins and uses thereof
MXPA06012960A (es) * 2004-05-07 2007-06-12 Phytotox Ltd Administracion transdermal de ficotoxinas.
US20050282836A1 (en) * 2004-06-22 2005-12-22 Weiyang Lin Solid orally ingestible formulations of tetrodotoxin
US20060034823A1 (en) * 2004-08-13 2006-02-16 Paul Reid Method of production and use of crotoxin as an analgesic
CN100363006C (zh) * 2004-08-20 2008-01-23 厦门朝阳生物工程有限公司 一种戒毒制剂及其制备方法
EP1799219A1 (de) * 2004-09-21 2007-06-27 Laboratorios del Dr. Esteve S.A. Tetrodotoxin und seine derivate zur behandlung von neuropathischen schmerzen mit ursprung im zentralen nervensystem
WO2006032459A1 (en) * 2004-09-22 2006-03-30 Laboratorios Del Dr. Esteve S.A. Tetrodotoxin and its derivatives for the treatment of peripheral-nervously derived neuropathic pain
PE20061036A1 (es) * 2005-02-11 2006-11-24 Esteve Labor Dr Bloqueadores del canal de sodio, tetrodotoxina o saxitoxina, como agentes para el tratamiento de la dependencia de nicotina
EP1714655A1 (de) * 2005-04-22 2006-10-25 Laboratorios Del Dr. Esteve, S.A. Verwendung eines Natriumkanalblockers und deren Analoga zur Behandlung von Nikotinabhängigkeit
EP1690541A1 (de) * 2005-02-11 2006-08-16 Laboratorios Del Dr. Esteve, S.A. Verwendung eines Natriumkanalblockers und deren Analoga zur Behandlung von Nikotinabhängigkeit
EP1702627A1 (de) * 2005-03-18 2006-09-20 Laboratorios Del Dr. Esteve, S.A. Analgetische Kombination aus Natriumkanalblocker und Opioid Antagonisten
EP1931349A4 (de) * 2005-08-25 2009-08-05 Wex Pharmaceuticals Inc Verwendung von natriumkanalblockern zur behanldung von muskel- und skelettschmerzen
WO2007025212A2 (en) * 2005-08-25 2007-03-01 Wex Pharmaceuticals, Inc. Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
US20070148159A1 (en) * 2005-12-22 2007-06-28 Reid Paul F Use of crotoxin as an analgesic - CIP
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
EP1844781A1 (de) 2006-02-22 2007-10-17 Wex Pharmaceuticals Inc. Verwendung von Natriumkanalblockern für die Behandlung von vorzeitigen Wehen
EP1844782A1 (de) * 2006-03-27 2007-10-17 Wex Pharmaceuticals, Inc 4,9-Anhydro-Tetrodoxin zur Behandlung von Krankheiten die in Zusammenhang mit der Potential-abhängigen Natrium-Kanal Subeinheit Nav1.6 stehen
WO2007110220A1 (en) * 2006-03-27 2007-10-04 Wex Pharmaceuticals Inc. USE OF 4,9-ANHYDRO-TETRODOTOXIN FOR THE TREATMENT OF DISEASES RELATED TO THE VOLTAGE-GATED SODIUM CHANNEL α SUBUNIT NAV 1.6
US9018222B2 (en) 2006-03-27 2015-04-28 Wex Medical Limited Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
EP1844783A1 (de) * 2006-03-27 2007-10-17 Wex Pharmaceuticals, Inc 4,9-Anhydro-Tetrodoxin zur Behandlung von Krankheiten die in Zusammenhang mit der Potential-abhängigen Natrium-Kanal Subeinheit Nav1.6 stehen
CN100438873C (zh) * 2006-06-26 2008-12-03 黄致强 将河鲀毒素作为镇痛药的耐受抑制剂在制备复方镇痛制剂中的应用
EP1882692A1 (de) * 2006-07-28 2008-01-30 Wex Pharmaceuticals Inc. Dimethano-[1,3]dioxocino[6,5-D]Pyrimidine-Spiro-Derivate von Tetrodotoxin, Verfahren ihrer Herstellung und ihre Verwendung zur Behandlung von Schmerzen
WO2009008997A2 (en) * 2007-07-06 2009-01-15 Nuon Therapeutics, Inc. Treatment of neuropathic pain
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
US8952152B2 (en) 2009-03-24 2015-02-10 Proteus S.A. Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof
WO2010117996A1 (en) * 2009-04-08 2010-10-14 Children's Medical Center Corporation Prolonged duration local anesthesia with minimal toxicity
JP6112867B2 (ja) * 2010-02-10 2017-04-12 ファイトトックス リミテッドＰｈｙｔｏｔｏｘ Ｌｉｍｉｔｅｄ サキシトキシン誘導体での触覚の喪失の処置
WO2012075337A2 (en) 2010-12-01 2012-06-07 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy
HK1220468A1 (zh) 2013-03-14 2017-05-05 Regeneron Pharmaceuticals, Inc. Nav1．7的人抗体
WO2014145580A1 (en) 2013-03-15 2014-09-18 The Children's Medical Center Corporation Neosaxitoxin combination formulations for prolonged local anesthesia
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
CN107198689A (zh) * 2017-07-11 2017-09-26 东新皓特（北京）生化科技有限公司 用于治疗疼痛病症的河豚毒素药物组合物及外用药
JP2024518821A (ja) 2021-04-23 2024-05-07 ウェクス ファーマシューティカルズ インコーポレイテッド テトロドトキシン液体製剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022899A (en) 1973-06-12 1977-05-10 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
US4029793A (en) 1973-06-12 1977-06-14 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
JPH09510221A (ja) * 1994-03-17 1997-10-14 ナンニン メープル リーフ ファーマスーティカル カンパニー リミテッド 薬物依存からの離脱のためのアミノ水素化キナゾリン化合物およびそれらの誘導体の用途
CN1072486C (zh) * 1996-09-24 2001-10-10 王维国 用于戒毒、镇痛的药剂及其制法
WO1998043619A2 (en) * 1997-04-02 1998-10-08 The Regents Of The University Of California Method of local anesthesia
US6326020B1 (en) * 1997-05-16 2001-12-04 Children's Medical Center Corporation Local anesthetic formulations
CN1236773C (zh) * 2000-11-22 2006-01-18 南宁枫叶药业有限公司 用于镇痛、麻醉或治疗药物依赖性的制剂
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用

Also Published As

Publication number Publication date
YU17103A (sh) 2006-03-03
BR0113961A (pt) 2004-01-13
ZA200301852B (en) 2004-06-21
EP1563839B1 (de) 2012-01-25
PL360616A1 (en) 2004-09-20
JP2004508404A (ja) 2004-03-18
EP1320369A4 (de) 2003-07-02
CN1284536C (zh) 2006-11-15
BG107690A (bg) 2004-01-30
NO20030915D0 (no) 2003-02-27
KR20030034181A (ko) 2003-05-01
NO20030915L (no) 2003-04-25
AU2002213785A1 (en) 2002-03-26
KR100891568B1 (ko) 2009-04-03
WO2002022129A1 (en) 2002-03-21
IS6719A (is) 2003-02-14
SK3732003A3 (sk) 2005-05-05
HUP0302677A3 (en) 2005-01-28
EA200300172A1 (ru) 2003-12-25
EP2298306B1 (de) 2013-09-11
DE60140466D1 (de) 2009-12-24
EP1320369B1 (de) 2009-11-11
EE200300106A (et) 2005-04-15
MXPA03002389A (es) 2004-03-12
NO323960B1 (no) 2007-07-23
EA004870B1 (ru) 2004-08-26
EP2298306A1 (de) 2011-03-23
CN1356104A (zh) 2002-07-03
UA76960C2 (en) 2006-10-16
IL154342A0 (en) 2003-09-17
EP1320369A1 (de) 2003-06-25
ES2435463T3 (es) 2013-12-19
EP1563839A1 (de) 2005-08-17
CA2421562A1 (en) 2002-03-21
HUP0302677A2 (hu) 2003-11-28
ATE542534T1 (de) 2012-02-15
US6407088B1 (en) 2002-06-18
HRP20030202A2 (en) 2005-02-28
KR20070112864A (ko) 2007-11-27
CA2421562C (en) 2011-05-24

Similar Documents

Publication Publication Date Title
ATE447959T1 (de) Methode zur reduktion des schmerzempfindens
WO2005013914A8 (en) Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
IL181700A0 (en) Quinazoline derivatives and pharmaceutical compositions containing the same
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
TW200510375A (en) New compounds
EP1708685A4 (de) Brauseformen von opiaten zur oralen anwendung und verfahren zur verabreichung von opiaten
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
BR0213449A (pt) Comprimido mastigável contendo lisina
WO2002007678A3 (en) Mu-conopeptides
WO2004087700A8 (fr) Derives du benzenesulfonamide, leur procede de preparation et leur utilisation de la douleur
EP1262197A3 (de) Kombinationstherapie zur Behandlung von Schlafstörungen, Schlaflosigkeit inbegriffen
HK1049104A1 (zh) 预防和治疗与感冒和类似感冒疾病相关的症状的方法和组合物
IL172423A0 (en) Novel formulations for opioid -based treatments of pain comprising substituted 1,4-di-piperidin-4-yl-piperazine derivatives
EP1387685A4 (de) Analgetische zusammensetzung und verfahren
WO2002005801A3 (en) Compositions containing diacyltartaric salts of (e)-metanicotine
WO2001060343A3 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und/oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
NZ523606A (en) Pharmaceutical compositions and methods for use
SE0000303D0 (sv) Novel compounds
TWI256388B (en) Pharmaceutical combination
WO2002076400A3 (en) Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
BR0313305A (pt) Agente analgésico para indivìduos recém-nascidos ou fetais
MY131159A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
WO2002009668A3 (en) Pulmonary administration of flint

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties